PHMR

The latest Market Access Alert is always available.

If you register you will also be able to view and search our complete Market Access Alert archive, and you will be notified when new Alerts are published.

New HTA Decisions in England

December 2021

Company

Drug name (generic name)

Therapeutic area

Decision

Company: Novo Nordisk

Drug: SAXENDA® (liraglutide)

Details: Obesity

TBD: Not recommended

View

Company: Lupin

Drug: NAMUSCLA® (mexiletine)

Details: Musculoskeletal conditions: general and other

TBD: Recommended

View

Company: AstraZeneca

Drug: LYNPARZA® (olaparib)

Details: Metastases

TBD: Not recommended

View

Company: Sanofi

Drug: DUPIXENT® (dupilumab)

Details: Asthma

TBD: Recommended with restrictions

View

Company: Kyowa Kirin

Drug: POTELIGEO® (mogamulizumab)

Details: Blood and bone marrow cancers

TBD: Recommended with restrictions

View

Company: Arvelle Therapeutics

Drug: ONTOZRY® (cenobamate)

Details: Epilepsy

TBD: Recommended with restrictions

View

Company: GlaxoSmithKline

Drug: BENLYSTA® (belimumab)

Details: Systemic lupus erythematosus

TBD: Recommended with restrictions

View

Company: Celgene

Drug: INREBIC® (fedratinib)

Details: Blood and bone marrow cancers

TBD: Recommended with restrictions (CDF)

View

Company: Roche

Drug: EVRYSDI® (risdiplam)

Details: Spinal conditions

TBD: Recommended

View